source
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with MerckBioPharma Dive’s latest data-visualization series charts Moderna’s dramatic stock rebound in 2026 after a period of decline. The company had struggled when demand for its COVID-19 vaccine fell, pr…
- FDA issues warning letters to drug makers over CGMP lapses and highlights patient rep ties to industry-backed groupsThe FDA has issued warning letters to several drug manufacturers for failing to meet current good manufacturing practice requirements, citing problems with ensuring product sterility and meeting sp…